Stabilitech collaborates with UCL on Grand Challenges Explorations programme
The goal of the programme is to create vaccines that can withstand the harsh extremes of heat and cold, and in doing so reduce the waste, cost and delay in immunisation programmes. If successful it will save countless lives from vaccine preventable deaths.
Stabilitech’s technology has the potential to stabilise vaccines including fragile live vaccines, both in a liquid or a lyophilized form, preventing losses caused by manufacturing stresses and thermal challenges, such as high and low temperature spikes, which are often seen during global distribution and provide for higher temperature storage. The chemical formulation system developed by Stabilitech is designed to easily fit with current manufacturing processes, which UCL Biochemical Engineering are already able to mimic at a small scale and validate at pilot scale. The combined technologies will demonstrate the applicability of the platforms to the development of more stable vaccines.
Please download the Press Release below to find out more.
|Stabilitech GCE Phase I Release_May 2012.pdf||96.82 KB|